Abstract
PURPOSEEpidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) show efficacy in treating patients with lung adenocarcinoma with EGFR-activating mutations. However, a significant s...
Cite
CITATION STYLE
APA
Su, S.-F., Liu, C.-H., Cheng, C.-L., Ho, C.-C., Yang, T.-Y., Chen, K.-C., … Li, K.-C. (2021). Genome-Wide Epigenetic Landscape of Lung Adenocarcinoma Links HOXB9 DNA Methylation to Intrinsic EGFR-TKI Resistance and Heterogeneous Responses. JCO Precision Oncology, (5), 418–431. https://doi.org/10.1200/po.20.00151
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free